The Croatian Model of NIH criteria Implementation
|
|
- Mary Bruce
- 5 years ago
- Views:
Transcription
1 The Croatian Model of NIH criteria Implementation Lana Grkovic, MD, UHC Zagreb, Zagreb, Croatia October 2014, Warsaw, Poland #EBMT2014
2 History of transplant at UHC Zagreb Haplo children Haplo AlloBMT Related donor MAC Autologous BMT UC 1989 AlloBMT Urelated donor 1992 HLA DNA-based RIC
3 AlloBMT at UHC Zagreb
4 RIC MAC
5 unrelated related 5 5
6 Organization of cgvhd program and clinical activity of the multidisciplinary team Visit of Prof. SZ Pavletic to the UHC Zagreb 6 6
7 Multidisciplinary team Professionals from a range of disciplines who work together to deliver comprehensive care that addresses as many of the patient's needs as possible. As a patient's condition changes over time, the composition of the team may change to reflect the changing clinical and psychosocial needs of the patient. Mitchell, G.K., Tieman, J.J. & Shelby-James, T.M. (2008). Multidisciplinary care planning and teamwork in primary care. MJA, 188(8), p.s
8 Results: Established cgvhd multidisciplinary team 8 8
9 Team members Hematology: Damir Nemet, Dražen Pulanić, Lana Grković, Ranka Serventi-Seiwerth, Radovan Vrhovac, Nadira Duraković, Zinaida Perić Pediatric Hematology: Ljubica Rajić, Ernest Bilić Nurse: Nikolina Matić Dental: Marinka Mravak Stipetić Neurology: Ervina Bilić Dermatology: Romana Čeović Ophthalmology: Igor Petriček PT: Tamara Vukić Gynecology: Tajana Klepac Pulanić, Slavko Orešković Nutritional: Dina Ljubas Immunology: Drago Batinić Transfusiology: Ines Bojanić ID: Davorka Dušek, Adriana Vince Molecular: Magdalena Grce, Renata Zadro GI: Željko Krznarić Pathology: Ivana Ilić Endocrinology: Zlatko Giljević HLA: Zorana Grubić PhD student: Ema Prenc Postdoc Iva Prah Steven Živko Pavletić- Collaborator 9 9
10 Day Hospital (Center for cgvhd and long term complications) 10 10
11 11 11
12 12 12
13 13 13
14 IRB approved informed consent signing H&P Laboratory workup Standard forms (NIH core sheet, form A and B..) Neurologic assessment and pain questionnaire QoL SF-36, Lee symptom scale, QLQ-C
15 cgvhd multidisciplinary team HEMATOLOGY DERMATOLOGY NUTRITION DENTAL PHYSICAL THERAPY HEPATOLOGY/GI ENDOCRINOLOGY PATIENT PULMONARY OPHTALMOLOGY INFECTIOUS DISEASE TRANSFUSIOLOGY GYNECOLOGY NEUROLOGY 15 15
16 Our results 16 16
17 17 17
18 QLQ-C30 = 30 questions five multi-item functional scales (Physical, Role, Emotional, Cognitive and Social Functioning) + combined Global Health Status/QoL scale Higher scores signify better functioning Nine symptom scales measure fatigue, pain, nausea,vomiting, dyspnea, sleep disturbances, appetite loss, diarrhoea, constipation and financial impact Higher scores represent greater symptomatology or impairments 18 18
19 Evaluation of QOL at UHC Zagreb SF-36 Results 19 19
20 Evaluation of QOL at UHC Zagreb QLQ- C30 Results 20 20
21 21 21
22 Ministry of science education and sports of the Republic of Croatia; Unity Through Knowledge Fund Project (2 years) Project title: Clinical and biological factors determining severity and activity of chronic Graft-versus-Host Disease after allogeneic hematopoietic stem cell transplantation Approx. $ 300, 000 (funded by World Bank and Ministry) Project Leader and Co-leader : prof. SZ Pavletic i prof. D. Nemet 8 Institutions participating: NCI/NIH, Medical School University of Zagreb, UHC Zagreb, School of Dental Medicine Zagreb, Institute Ruđer Bošković, KROHEM, University Hospital for Infectious Disease Dr. Fran Mihaljevic 22 22
23 CONNECTIVITY, COOPERABILITY, CREATIVITY C3 Mission: To unite scientific and professional potential in Croatia and Diaspora in development of the knowledge based society Goals: Ministry of science education and sports of the Republic of Croatia-Crossing Borders Grant; Unity Through Knowledge Fund Project 1) Supporting research that is competitive on international level 2) Fostering research that creates new values in Croatian economy 3) Supporting projects that help the development of research infrastructure in Croatia 23 23
24 Aims: Crossing Borders Grant To support outstanding Croatian scientists and professionals working and living abroad (Diaspora) in establishing scientific cooperation with local scientists (Croatian and foreign scientists working and living in Croatia), To foster Croatian institutions and enterprises to use potentials of Croatian scientific and professional Diaspora transfer of knowledge and attract investments to Croatian organization through cooperation between Diaspora and local scientists
25 Goals Establishment of the multidisciplinary team Comprehensive clinical, laboratory and imaging evaluation using NIH Consensus criteria Subspeciality evaluations focused on affected organs Creation of database and tissue and sera bank Subprojects New grant proposal application; collaboration with other Centers 25 25
26 First year results 32 cgvhd patients enrolled and 4 controls 8 abstracts published Oral presentation - Croatian society of hematology and transfusiology meeting with international participation, Rovinj, Croatia, March 2014 Grkovic L., Pulanic D., Serventi-Seiwerth R., Matic N., Mravak-Stipetic M., Ceovic R., Bilic E., Ljubas D., Rajic Lj., BIlic E., Durakovic N., Peric Z., Kovac K., Klepac Pulanic T., Dusek D., Bojanic I., Grce M., Petricek I., Batinic D., Vrhovac R., Pavletic S. Z., Nemet D. Formiranje multidisciplinarnog tima za liječenje kronične reakcije davatelja protiv primatelja i dugotrajnih komplikacija nakon transplantacije alogenih krvotvornih matičnih stanica u Kliničkom bolničkom centru Zagreb. Liječ Vjesn. 2014;136 (Supl 1.):
27 4 poster presentations Croatian society of hematology and transfusiology meeting with international participation, Rovinj, Croatia, March 2014 Bilić E., Grković L., Pulanić D., Serventi Seiwerth R., Bilić E., Vrhovac R., Nemet D., Pavletic SZ. Polyneuropathy in cgvhd patients Preliminar results. Liječ Vjesn. 2014;136 (Supl 1.):87. PRIZE FOR THE BEST POSTER Ljubas Kelecic D., Vranesic Bender D., Krznaric Z., Grkovic L., Pavletic S., Nemet D., Serventi Seiwerth R., Vrhovac R., Pulanic D. Nutritional status in patients with chronic GVHD. Liječ Vjesn. 2014;136 (Supl 1.):135. Pulanic D, Mravak-Stipetić M., Grkovic L., Serventi Seiwerth R., Vrhovac R., Nemet D., Sabol I., Grce M., Pavletic SZ. Oral manifestations in u cgvhd patients. Liječ Vjesn. 2014;136 (Supl 1.):89. Perić Z., Grkovic L., Pulanic D., Serventi-Seiwerth R., Matic N., Mravak-Stipetic M., Bilic E., Ceovic R., Ljubas D., Rajic Lj., BIlic E., Durakovic N., Klepac Pulanic T., Kovac K., Dusek D., Bojanic I., Grce M., Batinic D., Vrhovac R., Pavletic SZ., Nemet D. Quality of life after allogeneic stem cell transplantation. Liječ Vjesn. 2014;136 (Supl 1.):
28 EBMT, Milano, Italy, April L. Grkovic, D. Pulanic, R. Serventi-Seiwerth, N. Matic, M. Mravak-Stipetic, E. Bilic, R. Ceovic, D. Ljubas, Lj. Rajic, E. Bilic, N. Durakovic, Z. Peric, T. Klepac Pulanic, K. Kovac, D. Dusek, I. Bojanic, M. Grce, D. Batinic, R. Vrhovac, S.Z. Pavletic, D. Nemet. Implementation and dissemination of chronic Graft-versus-Host Disease NIH criteria and recommendations - formation of a multidisciplinary team and program at the University Hospital Center Zagreb, Croatia. Bone Marrow Transplant 49: S101-S385 (March 2014); doi: /bmt POSTER PRESENTATION M. Mravak-Stipetic, L. Grkovic, D. Pulanic, I. Sabol, M. Grce, D. Nemet, SZ Pavletic. Comprehensive evaluation of oral chronic graft versus host disease (cgvhd) in a cohort of Croatian patients. Bone Marrow Transplant 49: S438-S559 (March 2014); doi: /bmt PUBLICATION ONLY 28 28
29 Oral pressentation at international meeting EFNS-ENS Joint Congress of European Neurology May E. Bilic, L. Grkovic, D. Pulanic, E. Bilic, D. Nemet, SZ Pavletic. Small fiber neuropathy in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation - preliminary results of a prospective study. Europ J Neurology Abstract supplement,
30 Subprojects: Oral GVHD (trombocyte gel from autologous blood) Infections in cgvhd patients (HPV, EBV, CMV, polyoma virus, Candida albicans) Neurological cgvhd manifestations small fiber neuropathy (ENG and QST; pain detect questionnaire) Genital cgvhd Immunology (monocyte analysis from leukapheresis product; (CD16/CD163 i CD64/CD80) 30 30
31 Training at NIH, NCI Croatian members of cgvhd team (Past): Assist. Prof. Drazen Pulanic, MD, PhD (1 year) Ranka Serventi-Seiwerth, MD (3 months) Lana Grkovic, MD (1 year) PhD student and Post Doc hired (Present) PhD student visit to National Institutes of Health (Sep 2014) 31 31
32 Dissemination of the project results Web page 32 32
33 Interview; Croatian National Television 33 33
34 International Symposium Chronic GVHD and long term complications after hematopoietic stem cell transplantation, Zagreb, November
35 35 35
36 36 36
37 Development of the original database 37 37
38 Proposal submitted 38 38
39 Call PHC : Understanding common mechanisms of diseases and their relevance in comorbidities 39 39
40 Conclusions Multidisciplinary team established Comprehensive clinical, laboratory and imaging evaluation using NIH criteria Scientific activity Database developed PhD sudent and Postdoc hired New grant proposal submitted (HORIZON 2020) 40 40
41 THANK YOU! 41
PLATELETS AND COAGULATION IN CHRONIC GRAFT VERSUS HOST DISEASE
UDK 616.155.2 Review article Received: 4 June 2015 Accepted: 16 September 2015 PLATELETS AND COAGULATION IN CHRONIC GRAFT VERSUS HOST DISEASE Dražen Pulanić a,b,c a Division of Hematology, University Department
More informationImpressum Bilten Krohema Publisher: For publisher: Editor in Chief: Secretary of the Editorial Board: Editorial Board: Secretary of the CROHEM:
Impressum Bilten Krohema The Journal of the Croatian Cooperative Group for Hematological Diseases CROHEM Volume 8, Supplement 1, September 2016 Publisher: Croatian Cooperative Group for Hematological Diseases
More information4nd Patient and Family Day
4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,
More informationProtecting Your Health After Transplant (Adults)
Protecting Your Health After Transplant (Adults) Navneet Majhail, MD, MS Medical Director, Health Services Research, National Marrow Donor Program Adjunct Associate Professor of Medicine, University of
More informationPERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey
PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey Joint Educational Meeting of the EBMT Severe Aplastic Anaemia, Late Effects and Autoimmune Diseases Working Parties
More informationNothing to disclose. Title of the presentation - Author
Nothing to disclose Title of the presentation - Author 1 www.ebmt.org Complications after HSCT Alicia Rovó MD London 9/04/2013 Introduction Risk factors for transplant complication Type of complications
More informationBMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationIntroduction. Graft Versus Host Disease: Living With the After Effects of Bone Marrow/Stem Cell Transplant
Graft Versus Host Disease: Living With the After Effects of Bone Marrow/Stem Cell Transplant Introduction Chronic Graft versus Host Disease (cgvhd) occurs after a transplant when the immune system of the
More informationSurvivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life
1 Survivorship After Allogeneic Stem Cell Transplantation: Monitoring, Management and Quality of Life Stephanie J. Lee, MD, MPH Fred Hutchinson Cancer Research Center April 16, 2016 (40 min) Hematopoietic
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationNational Drugs Monitoring System in Croatia (JHA 53303)
TAIEX workshop on National Drugs Monitoring System in Croatia (JHA 53303) organised by TAIEX (Technical Assistance and Information Exchange Instrument) of the European Commission, in co-operation with
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationThe Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014
The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014 Worldwide Network for Blood and Marrow Transplantation Transplants A Little
More informationSylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.
Bone Marrow Research Volume 2012, Article ID 873695, 5 pages doi:10.1155/2012/873695 Clinical Study Both Optimal Matching and Procedure Duration Influence Survival of Patients after Unrelated Donor Hematopoietic
More informationLate complications after hematopoietic stem cell transplant in adult patients
Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France Synopsis H S C T Allogeneic HSCT activity
More informationDeveloping a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES:
Developing a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES: 1. To discuss the process that NYUHC Oncology Nursing Services used to develop and maintain a quality dashboard. 2. To define
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationNeglected deficiencies in severe malnutrition: phosphate and thiamine Case-based introduction A-M. Liberati-Cizmek (Croatia)
ESPEN Congress Vienna 2009 Neglected deficiencies in severe malnutrition: phosphate and thiamine Case-based introduction A-M. Liberati-Cizmek (Croatia) Neglected deficiencies in severe malnutrition: thiamine
More informationDisclosure. Objectives 1/22/2015
Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North
More informationJoint and fascial chronic graftvs-host disease: correlations with clinical and laboratory parameters
266 GRAFT-VS-HOST DISEASE Croat Med J. 2016;57:266-75 doi: 10.3325/cmj.2016.57.266 Joint and fascial chronic graftvs-host disease: correlations with clinical and laboratory parameters Aim To determine
More informationObjectives. Describe a multidisciplinary team and it s utilization in the inpatient cardiovascular surgical patient
None Endorsements Objectives Describe a multidisciplinary team and it s utilization in the inpatient cardiovascular surgical patient Understand clinical and clinician benefits of a multidisciplinary team
More informationSummary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationSurvivorship After Stem Cell Transplantation and Long-term Followup
Survivorship After Stem Cell Transplantation and Long-term Followup Navneet Majhail, MD, MS Director, Blood & Marrow Transplant Program, Cleveland Clinic Professor, Cleveland Clinic Lerner College of Medicine
More informationAre We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017
Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell Ann Haight, MD 9 Sept 2017 Spoiler alert Yes (we have a cure) And No Work to do! 2 Sickle Cell Treatment Options Supportive Care
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationTwenty-five-years history of the Department of Immunology at the Children s Memorial Health Institute in Warsaw
Immunological forum Twenty-five-years history of the Department of Immunology at the Children s Memorial Health Institute in Warsaw EWA BERNATOWSKA This year the Department of Immunology at the Children
More informationNEWS FROM. Roswell Park s BLOOD AND MARROW TRANSPLANT PROGRAM
NEWS FROM Roswell Park s BLOOD AND MARROW TRANSPLANT PROGRAM THE BLOOD AND MARROW TRANSPLANT TEAM Philip McCarthy, MD Medical Director, BMT Program Hong Liu, MD, PhD Attending Physician Our multidisciplinary
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationHow to prevent Infections in Patients undergoing allo-hsct?
How to prevent Infections in Patients undergoing allo-hsct? Olaf Penack EBMT Course, 29 Sept 1 Oct 2014, Naples, Italy #EBMT2014 www.ebmt.org Prevention of Infections Epidemiology and risk factors for
More informationIntegrating Palliative and Oncology Care in Patients with Advanced Cancer
Integrating Palliative and Oncology Care in Patients with Advanced Cancer Jennifer Temel, MD Massachusetts General Hospital Cancer Center Director, Cancer Outcomes Research Overview 1. Why should we be
More informationLate Complications. Objectives. Long-term Survival after HCT. Long-term Survival and Late Complications after HCT. Long-term Survival after HCT
Objectives Late Complications Navneet Majhail, MD, MS Review late complications in hematopoietic cell transplant (HCT) recipients Review screening and prevention guidelines for HCT survivors Review upcoming
More informationLate Complications. Navneet Majhail, MD, MS
Late Complications Navneet Majhail, MD, MS Medical Director, Health Services Research, NMDP Assistant Scientific Director, CIBMTR Adjunct Associate Professor of Medicine University of Minnesota Objectives
More informationWorkshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan
Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationDonor work up, follow up and ethical issues
Donor work up, follow up and ethical issues Hans Hägglund MD. PhD. Associate Professor Hematology Center, Karolinska University Hospital, Stockholm, Sweden Outline The donor has been identified as a match
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationResearch Status up to Date
(File of Details of Application) 2. Research Status up to Date (Describe the status specifically; chart/diagram may be included. Change/addition of the form is not allowed. (The same shall apply hereafter))
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationEBV in HSCT 2015 update of ECIL guidelines
ECIL-6 EBV in HSCT 2015 update of ECIL guidelines Jan Styczynski (Poland, chair), Walter van der Velden (Netherlands), Christopher Fox (United Kingdom), Dan Engelhard (Israel), Rafael de la Camara (Spain),
More informationCARE-NMD results. Jan Kirschner
CARE-NMD results Jan Kirschner TREAT-NMD Alliance Meeting Newcastle 30 Oct -1 Nov 2013 Care recommendations for DMD Consensus process 2 Care recommendations for DMD Consensus process Scientific publication
More informationClinical Trials: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Clinical Trials: Questions
More informationLynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines
Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines 3. WBMT Workshop 14-15 November 2014 Cape Town, South Africa Department for Hematology and Medical Oncology Leipzig,
More informationRelated haploidentical donors versus matched unrelated donors
Related haploidentical donors versus matched unrelated donors Bronwen Shaw, MD PhD Professor of Medicine, MCW Senior Scientific Director, CIBMTR Definition Matched Unrelated donor Refers to HLA matching
More informationAAP Immunization Initiatives JILL HERNANDEZ, MPH
AAP Immunization Initiatives JILL HERNANDEZ, MPH AAP Structure The AAP Today 62,000 members 10 districts 66 state/local chapters 26 national committees 50 sections 11 councils 500 staff Illinois, Washington
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationRituximab, and autologous stem cell collection rate after induction therapy with Bortezomib-Rituximab. 4 Not yet recruiting
1 Recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Conditions: Waldenstrom's ; Waldenstrom Macroglobulinaemia Intervention: Biological: Ofatumumab Sponsor: GlaxoSmithKline Number
More informationStem cell Survivorship: Searching for a solution to our success. Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic
Stem cell Survivorship: Searching for a solution to our success Rich Boyajian NP Clinical Director of the LAF ad u lt su rvivorship clinic Location of Centers Participating in t he CI BMTR 2 0 0 7................................................................................................................
More informationLate effects after HSCT
Late effects after HSCT Yves Chalandon Hematology Division, University Hospital of Geneva (HUG) Switzerland Hôpitaux Universitaires de Genève Company name Disclosures of: Yves Chalandon Research support
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationBlood & Marrow Transplant Leukemia Immunotherapy
Blood & Marrow Transplant Leukemia Immunotherapy Our Physicians Our specially trained physicians provide leadership for the Northside Hospital Blood and Marrow Transplant, Leukemia and Immunotherapy Programs,
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationAcute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University
Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against
More information87 Telemedicine sites
Children s - Largest Pediatric Provider in U.S. Scottish Rite Egleston Hughes Spalding 28 7 Neighborhood Locations Urgent Care Centers 87 Telemedicine sites 1 We re Growing Outpatient Care Center at Town
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationOffice of Clinical Research Annual Report 2017 July 1, June 30, 2017
Office of Clinical Research Annual Report 2017 July 1, 2016- June 30, 2017 Table of Contents Title Page Number Mission Statement 1 Objective 1 Research Services 1 Research Highlights 2 Figure 1 Number
More informationMichael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4
Twice-weekly Brincidofovir (BCV, CMX1) Shows Promising Antiviral Activity in Immunocompromised Transplant Patients with Asymptomatic Adenovirus Viremia Michael Grimley 1, Vinod Prasad, Joanne Kurtzberg,
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationWorld Premier International Research Center (WPI) Initiative General Comments on FY2007 WPI Project Progress by Program Committee
World Premier International Research Center (WPI) Initiative General Comments on FY2007 WPI Project Progress by Program Committee WPI Research Centers In October 2007, the Ministry of Education, Culture,
More informationBack to the Future: The Resurgence of Bone Marrow??
Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow
More informationUNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE
UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest
More informationEBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation
EBMT EBMT Organisation and Activities J Apperley 13th. ESH-EBMT Training Course Targu Mures May 24 26, 2010 History Organisation Studies Activity Philosophy EBMT Website www.ebmt.org EBMT Society European
More informationCOPING STRATEGIES IN CHILDREN WITH HEADACHES
COPING STRATEGIES IN CHILDREN WITH HEADACHES Anita Vulić-Prtorić Department of Psychology, University of Zadar, Croatia Renata Coha Department of Pediatrics, General Hospital Josip Benčević, Slavonski
More informationACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology
ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology ACGME approved: June 27, 2006; effective: July 1, 2007 ACGME approved focused revision: September 30, 2012; effective:
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationHAEMATOPOIETIC STEM CELL TRANSPLANTATION
PRIMARY IMMUNODEFICIENCIES HAEMATOPOIETIC STEM CELL TRANSPLANTATION HAEMATOPOIETIC STEM CELL TRANSPLANTATION 1 PRIMARY IMMUNODEFICIENCIES KEY ABBREVIATIONS CID GvHD HSCT IPOPI PID SCID BMT HSC Combined
More informationBibliometric study on Dutch academic medical centers /2014
NFU-kenmerk: 5.783 Registratiedatum: 3-7-205 Bibliometric study on Dutch academic medical centers 998-203/204 Research report to the Deans of Medical Sciences (DMW) in the Netherlands June 205 Center for
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationNational Center for Child Health and Development Organ Transplantation Center
National Center for Child Health and Development Organ Transplantation Center A t the division of transplantation center in NCCHD, we have a mission to save children s life who have been suffered from
More informationSickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?
Sickle Cell Diseasechronic illness or curable disease? Gregory M.T. Guilcher MD, FRCPC, FAAP Objectives To review the general principles of hematopoietic stem cell transplantation (HSCT), including risks
More informationBone Marrow (Stem Cell) Transplant for Sickle Cell Disease
Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children s Research Hospital Departments of Hematology, Patient
More informationBlood & Marrow Transplantation Center
Blood & Marrow Transplantation Center We were one of the first centers in the world to routinely offer patients blood and marrow transplantation (BMT). What Sets Us Apart High-volume center performs about
More informationthe Office of Research Application Portal: Materials to submit:
Title: PAR 17 237: Centers for AIDS Research (P30) Slots: 1 Internal Deadline: LOI: External Deadline: Award Information: Submission Process: May 26, 2018, 5pm PDT 30 days prior to the application due
More informationState of the Art of Rare Disease Activities in EU Member States and Other European Countries Croatia Report
State of the Art of Rare Disease Activities in EU Member States and Other European Countries Croatia Report Definition of a Rare Disease Croatia has adopted the European Commission definition of a rare
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationStem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT
Stem cells -Dr Dinesh Bhurani, MD, DM, FRCPA -Director, Department of Haematology and BMT Rajiv Gandhi Cancer Institute, Delhi, Flow of presentation Update on stem cell uses Haematopoietic stem cell transplantation
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationFebruary Company Overview. Curative Treatments for Cancer and Orphan Genetic Diseases
February 2017 Company Overview Curative Treatments for Cancer and Orphan Genetic Diseases Curative Treatments for Orphan Indications NiCord - a bone marrow transplantation treatment for patients with high
More informationBlood and Marrow Transplant (BMT) for Sickle Cell Disease
Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationFogarty Initiatives for Building Capacity in HIV/AIDS
Fogarty Initiatives for Building Capacity in HIV/AIDS April 13, 2010 Michael P. Johnson, M.D., M.P.H Deputy Director Fogarty International Center Global Health Transition in 21 st Century the unfinished
More informationSummary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale
BMT CTN 1101 RIC ducb vs. Haplo Page 1 of 10 Date: January 20, 2017 Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, 2017 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC)
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationLONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS
LONG TERM FOLLOW-UP OF PATIENTS WITH FANCONI ANEMIA AFTER ALLOGENEIC T-CELL DEPLETED HEMATOPOITEIC STEM CELL TRANSPLANTATION FROM ALTERNATIVE DONORS Farid Boulad, Susan E Prockop, Praveen Anur, Danielle
More informationIntegration of Acute and Chronic Graft-Versus-Host Disease Assessments into the Inpatient Electronic Medical Record
Integration of Acute and Chronic Graft-Versus-Host Disease Assessments into the Inpatient Electronic Medical Record Madhu Ragupathi, MD Research Analyst II Charles A. Sammons Cancer Center at Baylor University
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/28461 holds various files of this Leiden University dissertation. Author: Brink, Marloes Hendrika ten Title: Individualized therapeutics in allogeneic stem
More informationGeneral Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin
Glossary of Terms This appendix is divided into two sections. The first section, General Terms, defines terms used throughout the CIBMTR data collection forms. The second section, FormsNet TM 2 Terms,
More information